{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T01:43:16Z","timestamp":1755999796637},"reference-count":41,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The outcome of chronic myeloid leukemia (CML) patients in chronic phase has\nchanged after the introduction of tyrosine kinase inhibitors (TKIs). The life expectancy is actually similar\nto that of the general population. Although outstanding results were achieved, about 20-30% of patients\nfailed to achieve molecular milestones or experienced a severe toxicity and needed to switch to a second\nline.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The aim of this review is to report on possible future management in CML, from dose optimization\nto avoid long-term off-target events to new agents for the treatment of resistant and\/or intolerant\npatients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Broad research on Medline, Embase and archives from EHA and ASH congresses was performed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>New TKIs have been developed to counteract resistance and\/or intolerance in the setting of\nT315I mutated patients. The benefits of ponatinib dose optimization have been recently reported in the\nOPTIC trial. New trials to test the dose optimization are ongoing.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Reduction of the standard dose could be performed to reduce the specific TKI toxicity. Selective\nTKIs could be prescribed in the future as third line treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568009622666220613144253","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T06:22:35Z","timestamp":1655274155000},"page":"796-805","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Future Management of Chronic Myeloid Leukemia: From Dose Optimization\nto New Agents"],"prefix":"10.2174","volume":"22","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Scalzulli","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Pepe","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gioia","family":"Colafigli","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Martelli","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fonc.2019.00603","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez V.","year":"2019","unstructured":"Garc\u00eda-Guti\u00e9rrez V.; Hern\u00e1ndez-Boluda J.C.; Tyrosine kinase inhibitors available for chronic myeloid leukemia: Efficacy and safety. Front Oncol 2019,9,603","journal-title":"Front Oncol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"Bower H.","year":"2016","unstructured":"Bower H.; Bj\u00f6rkholm M.; Dickman P.W.; H\u00f6glund M.; Lambert P.C.; Andersson T.M.; Life expectancy of patients with chronic mye-loid leukemia approaches the life expectancy of the general population. J Clin Oncol 2016,34(24),2851-2857","journal-title":"J Clin Oncol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/leu.2016.246","volume":"31","author":"Hoffmann V.S.","year":"2017","unstructured":"Hoffmann V.S.; Baccarani M.; Hasford J.; Castagnetti F.; Di Raimondo F.; Casado L.F.; Turkina A.; Zackova D.; Ossenkoppele G.; Zaritskey A.; H\u00f6glund M.; Simonsson B.; Indrak K.; Sninska Z.; Sacha T.; Clark R.; Bogdanovic A.; Hellmann A.; Griskevicius L.; Schubert-Fritschle G.; Sertic D.; Guilhot J.; Lejniece S.; Zupan I.; Burgstaller S.; Koskenvesa P.; Everaus H.; Costeas P.; Lindoerfer D.; Rosti G.; Saussele S.; Hochhaus A.; Hehlmann R.; Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia 2017,31(3),593-601","journal-title":"Leukemia"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"Cortes J.E.","year":"2016","unstructured":"Cortes J.E.; Saglio G.; Kantarjian H.M.; Baccarani M.; Mayer J.; Boqu\u00e9 C.; Shah N.P.; Chuah C.; Casanova L.; Bradley-Garelik B.; Manos G.; Hochhaus A.; Final 5-year study results of dasision: The dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol 2016,34(20),2333-2340","journal-title":"J Clin Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"Hochhaus A.","year":"2016","unstructured":"Hochhaus A.; Saglio G.; Hughes T.P.; Larson R.A.; Kim D.W.; Issaragrisil S.; le Coutre P.D.; Etienne G.; Dorlhiac-Llacer P.E.; Clark R.E.; Flinn I.W.; Nakamae H.; Donohue B.; Deng W.; Dalal D.; Menssen H.D.; Kantarjian H.M.; Long-term benefits and risks of front-line nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016,30(5),1044-1054","journal-title":"Leukemia"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","volume":"36","author":"Cortes J.E.","year":"2018","unstructured":"Cortes J.E.; Gambacorti-Passerini C.; Deininger M.W.; Mauro M.J.; Chuah C.; Kim D.W.; Dyagil I.; Glushko N.; Milojkovic D.; le Coutre P.; Garcia-Gutierrez V.; Reilly L.; Jeynes-Ellis A.; Leip E.; Bardy-Bouxin N.; Hochhaus A.; Br\u00fcmmendorf T.H.; Bosutinib ver-sus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized bfore trial. J Clin Oncol 2018,36(3),231-237","journal-title":"J Clin Oncol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1002\/cam4.3071","volume":"9","author":"Breccia M.","year":"2020","unstructured":"Breccia M.; Olimpieri P.P.; Olimpieri O.; Pane F.; Iurlo A.; Foggi P.; Cirilli A.; Colatrella A.; Cuomo M.; Gozzo L.; Summa V.; Cor-radini P.; Russo P.; How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA). Cancer Med 2020,9(12),4160-4165","journal-title":"Cancer Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","volume":"117","author":"Kantarjian H.M.","year":"2011","unstructured":"Kantarjian H.M.; Giles F.J.; Bhalla K.N.; Pinilla-Ibarz J.; Larson R.A.; Gattermann N.; Ottmann O.G.; Hochhaus A.; Radich J.P.; Sa-glio G.; Hughes T.P.; Martinelli G.; Kim D.W.; Shou Y.; Gallagher N.J.; Blakesley R.; Baccarani M.; Cortes J.; le Coutre P.D.; Ni-lotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011,117(4),1141-1145","journal-title":"Blood"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","volume":"123","author":"Shah N.P.","year":"2014","unstructured":"Shah N.P.; Guilhot F.; Cortes J.E.; Schiffer C.A.; le Coutre P.; Br\u00fcmmendorf T.H.; Kantarjian H.M.; Hochhaus A.; Rousselot P.; Mohamed H.; Healey D.; Cunningham M.; Saglio G.; Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: Follow-up of a phase 3 study. Blood 2014,123(15),2317-2324","journal-title":"Blood"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","volume":"4","author":"Clark R.E.","year":"2017","unstructured":"Clark R.E.; Polydoros F.; Apperley J.F.; Milojkovic D.; Pocock C.; Smith G.; Byrne J.L.; de Lavallade H.; O\u2019Brien S.G.; Coffey T.; Foroni L.; Copland M.; De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major mo-lecular response (DESTINY): An interim analysis of a non-randomised, phase 2 trial. Lancet Haematol 2017,4(7),e310-e316","journal-title":"Lancet Haematol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"Clark R.E.","year":"2019","unstructured":"Clark R.E.; Polydoros F.; Apperley J.F.; Milojkovic D.; Rothwell K.; Pocock C.; Byrne J.; de Lavallade H.; Osborne W.; Robinson L.; O\u2019Brien S.G.; Read L.; Foroni L.; Copland M.; De-escalation of tyrosine kinase inhibitor therapy before complete treatment discon-tinuation in patients with chronic myeloid leukaemia (DESTINY): A non-randomised, phase 2 trial. Lancet Haematol 2019,6(7),e375-e383","journal-title":"Lancet Haematol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood.2019003395","volume":"135","author":"Gottschalk A.","year":"2020","unstructured":"Gottschalk A.; Glauche I.; Cicconi S.; Clark R.E.; Roeder I.; Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML. Blood 2020,135(10),766-769","journal-title":"Blood"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1200\/JCO.2021.39.15_suppl.7000","volume":"39","author":"Cortes E.J.","year":"2021","unstructured":"Cortes E.J.; Apperley J.; Lomaia E.; Moiraghi B.; Undurraga Sutton M.; Pavlovsky C.; Chuah C.; Sacha T.; Lipton J.H.; Schiffer C.; Deininger M.W.; OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON). J Clin Oncol 2021,39,7000","journal-title":"J Clin Oncol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.2021012082","volume":"138","author":"Cortes J.","year":"2021","unstructured":"Cortes J.; Apperley J.; Lomaia E.; Moiraghi B.; Undurraga Sutton M.; Pavlovsky C.; Chuah C.; Sacha T.; Lipton J.H.; Schiffer C.A.; McCloskey J.; Hochhaus A.; Rousselot P.; Rosti G.; de Lavallade H.; Turkina A.; Rojas C.; Arthur C.K.; Maness L.; Talpaz M.; Mauro M.; Hall T.; Lu V.; Srivastava S.; Deininger M.; Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: A randomized, open-label phase 2 clinical trial. Blood 2021,138(21),2042-2050","journal-title":"Blood"},{"key":"ref=15","first-page":"318","volume":"130","author":"Rea D.","year":"2017","unstructured":"Rea D.; Cayuela J.M.; Dulucq S.; Etienne G.; Molecular responses after switching from a standard-dose twice-daily nilotinib regimen to a reduced-dose once-daily schedule in patients with chronic myeloid leukemia: A real life observational study (NILO-RED). Blood 2017,130(23),318","journal-title":"Blood"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1182\/blood-2021-145411","volume":"138","author":"Breccia M.","year":"2021","unstructured":"Breccia M.; Abruzzese E.; Stagno F.; Iurlo A.; Pane F.; Attolico I.; Sportoletti P.; Pregno P.; Galimberti S.; Scappini B.; Lemoli R.M.; Siragusa S.; Capodanno I.; Chiodi F.; Saglio G.N.; Rosti G.; First intermin analysis of the italian dante study: De-esacaltion before treat-ment-free remission in patients with chronic myeloid leukemia treated with first-line nilotinib. Blood 2021,138(Suppl. 1),1474","journal-title":"Blood"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"Hughes T.P.","year":"2019","unstructured":"Hughes T.P.; Mauro M.J.; Cortes J.E.; Minami H.; Rea D.; DeAngelo D.J.; Breccia M.; Goh Y.T.; Talpaz M.; Hochhaus A.; le Coutre P.; Ottmann O.; Heinrich M.C.; Steegmann J.L.; Deininger M.W.N.; Janssen J.J.W.M.; Mahon F.X.; Minami Y.; Yeung D.; Ross D.M.; Tallman M.S.; Park J.H.; Druker B.J.; Hynds D.; Duan Y.; Meille C.; Hourcade-Potelleret F.; Vanasse K.G.; Lang F.; Kim D.W.; Asciminib in chronic myeloid leukemia after ABl kinase inhibitor failure. N Engl J Med 2019,381(24),2315-2326","journal-title":"N Engl J Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"Wylie A.A.","year":"2017","unstructured":"Wylie A.A.; Schoepfer J.; Jahnke W.; Cowan-Jacob S.W.; Loo A.; Furet P.; Marzinzik A.L.; Pelle X.; Donovan J.; Zhu W.; Buonami-ci S.; Hassan A.Q.; Lombardo F.; Iyer V.; Palmer M.; Berellini G.; Dodd S.; Thohan S.; Bitter H.; Branford S.; Ross D.M.; Hughes T.P.; Petruzzelli L.; Vanasse K.G.; Warmuth M.; Hofmann F.; Keen N.J.; Sellers W.R.; The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 2017,543(7647),733-737","journal-title":"Nature"},{"key":"ref=19","first-page":"S884","volume":"2019","author":"Mauro M.J.","year":"2019","unstructured":"Mauro M.J.; Kim D.W.; Cortes J.; R\u00e9a D.; Hughes T.P.; Minami H.; Breccia M.; DeAngelo D.J.; Talpaz M.; Hochhaus A.; Goh Y.T.; le Coutre P.D.; Sondhi M.; Mishra K.; Hourcade-Potelleret F.; Vanasse G.; Aimone P.; Lang F.; Combination of asciminib plus ni-lotinib (NIL) or dasatinib (DAS) in patients (pts) with chronic myeloid leukemia (CML): Results from a phase 1 study. EHA 2019,2019,S884","journal-title":"EHA"},{"key":"ref=20","first-page":"S883","volume":"2019","author":"Cortes J.","year":"2019","unstructured":"Cortes J.; Lang F.; Kim D.W.; R\u00e9a D.; Mauro M.J.; Minami H.; Breccia M.; DeAngelo D.J.; Talpaz M.; Hochhaus A.; Goh Y.T.; le Coutre P.D.; Sondhi M.; Mishra K.; Hourcade-Potelleret F.; Vanasse G.; Aimone P.; Hughes T.P.; Combination therapy using ascimin-ib plus imatinib (ima) in patients with chronic myeloid leukemia (CML): Results from a phase 1 study. EHA 2019,2019,S883","journal-title":"EHA"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/blood-2020-139677","volume":"136","author":"Cortes J.","year":"2020","unstructured":"Cortes J.; Hughes T.P.; Mauro M.J.; Hochhaus A.; R\u00e9a D.; Goh Y.T.; Janssen J.; Steegmann J.L.; Heinrich M.C.; Talpaz M.; Etienne G.; Breccia M.; Deininger M.W.; le Coutre P.D.; Lang F.; Aimone P.; Polydoros F.; Cacciatore S.; Stenson L.; Kim D.W.; Asciminib, a First-in-Class STAMP Inhibitor, provides durable molecular response in patients (pts) with chronic myeloid leukemia (CML) harboring the T315I mutation: Primary efficacy and safety results from a phase 1 trial. Blood 2020,136(Suppl. 1),47-50","journal-title":"Blood"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-143816","volume":"136","author":"Hochhaus A.","year":"2020","unstructured":"Hochhaus A.; Boquimpani C.; Rea D.; Minami Y.; Lomaia E.; Voloshin S.; Turkina A.G.; Kim D.W.; Apperley J.; Cortes J.E.; Abdo A.; Fogliatto L.M.; Kim D.D.H.; le Coutre P.D.; Saussele S.; Annunziata M.; Hughes T.P.; Chaudhri N.A.; Chee L.C.Y.; Guti\u00e8rrez V.G.; Sasaki K.; Aimone P.; Allepuz A.; Quenet S.; B\u00e8doucha V.; Mauro M.J.; Efficacy and safety results from ASCEMBL, a multicen-ter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs. bosutinib in patients with chronic myeloid leukemia in chronic phase previously treated with > 2 tyrosine kinase inhibitors. Blood 2020,136(s1)(Suppl. 2)","journal-title":"Blood"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"R\u00e9a D.","year":"2021","unstructured":"R\u00e9a D.; Mauro M.J.; Boquimpani C.; Minami Y.; Lomaia E.; Voloshin S.; Turkina A.; Kim D.W.; Apperley J.F.; Abdo A.; Fogliatto L.M.; Kim D.D.H.; le Coutre P.; Saussele S.; Annunziata M.; Hughes T.P.; Chaudhri N.; Sasaki K.; Chee L.; Garc\u00eda-Guti\u00e9rrez V.; Cortes J.E.; Aimone P.; Allepuz A.; Quenet S.; B\u00e9doucha V.; Hochhaus A.; A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs. bosutinib in CML after 2 or more prior TKIs. Blood 2021,138(21),2031-2041","journal-title":"Blood"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.exphem.2019.08.007","volume":"77","author":"Antelope O.","year":"2019","unstructured":"Antelope O.; Vellore N.A.; Pomicter A.D.; Patel A.B.; Van Scoyk A.; Clair P.M.; Deininger M.W.; O\u2019Hare T.; BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia. Exp Hematol 2019,77,36-40.e2","journal-title":"Exp Hematol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1182\/blood-2019-129751","volume":"134","author":"Cortes J.E.","year":"2019","unstructured":"Cortes J.E.; Kim D.W.; Nicolini F.E.; Saikia T.; Charbonnier A.; Apperley J.F.; Rathnam K.; Deininger M.W.; De Lavallade H.; Khattry N.; Whiteley A.; Mauro M.J.; Verhoef G.; Gambacorti-Passerini C.; Lucchesi A.; Apte S.; Nikki G.; Yao S.L.; Kothekar M.; Sreenivasan J.; Bimba H.V.; Chimote G.; Phase 1 Trial of K0706, a novel oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In patients with chronic myelogenous leukemia (CML) and phildelphia positive acute lymphoblastic leukemia (Ph+ ALL) failing \u2265 3 prior TKI thera-pies: Initial safety and efficacy. Blood 2019,134(Suppl. 1),4158","journal-title":"Blood"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1182\/blood-2020-139847","volume":"136","author":"Cortes J.E.","year":"2020","unstructured":"Cortes J.E.; Saikia T.; Kim D.W.; Alvarado Y.; Nicolini F.E.; Khattry N.; Rathnam K.; Apperley J.; Deininger M.W.; de Lavallade H.; Charbonnier A.; Granacher N.; Gambacordi-Passarini C.; Lucchesi A.; Mauro M.J.; Verhoef G.; Vandenberghe P.; Whiteley A.R.; Apte S.; Yao S.L.; Kothekar M.; Sreenivasan J.; Bimba H.V.; Chimote G.; Phase 1 trial of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): Activity in CML chronic phase patients failing TKI therapies including ponatinib. Blood 2020,136(Suppl. 1),51-52","journal-title":"Blood"},{"key":"ref=27","author":"Cortes J.E.","unstructured":"Cortes J.E.; Saikia T.; Kim D.W.; Alvarado Y.; Nicolini F.E.; Rathnam K.; Khattry N.; Apperley J.; Deininger M.W.; de Lavallade H.; Charbonnier A.; Granacher N.; Gambacordi-Passarini C.; Lucchesi A.; Mauro M.J.; Vandenberghe P.; Verhoef G.; Whiteley A.R.; Nag A.; Radhakrishnan V.S.; Apte S.; Yao S.L.; Inamdar S.; Sreenivasan J.; Dillu R.I.; Chimote G.; An update of safety and efficacy results from Phase 1 Dose-\nEscalation and Expansion Study of Vodobatinib, a novel oral BCRABL1\nTyrosine Kinase Inhibitor (TKI), in patients with Chronic\nMyeloid Leukemia (CML) and Philadelphia Chromosome Positive\nAcute Lymphoblastic Leukemia (Ph+ ALL) failing prior TKI therapies.\nBlood, 2021, 138(supplement 2), abstract 309."},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1021\/jm301581y","volume":"56","author":"Ren X.","year":"2013","unstructured":"Ren X.; Pan X.; Zhang Z.; Wang D.; Lu X.; Li Y.; Wen D.; Long H.; Luo J.; Feng Y.; Zhuang X.; Zhang F.; Liu J.; Leng F.; Lang X.; Bai Y.; She M.; Tu Z.; Pan J.; Ding K.; Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem 2013,56(3),879-894","journal-title":"J Med Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1182\/blood-2019-124295","volume":"134","author":"Jiang Q.","year":"2019","unstructured":"Jiang Q.; Huang X.; Chen Z.; Niu Q.; Men L.; Wang H.; Jl J.; Huang B.; Shi D.; Zhao T.; Hou Y.; Yang D.; Zhai Y.; An updated safety and efficacy results of Phase 1 Study of HQP1351, a novel 3rd generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in pa-tients with TKI resistant Chronic Myeloid Leukemia. Blood 2019,134(Suppl. 1),493","journal-title":"Blood"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2021-153065","volume":"138","author":"Jiang Q.","year":"2021","unstructured":"Jiang Q.; Shi D.; Li Z.; Qin Y.; Zhao T.; Liu B.; Chen Z.; Niu Q.; Men L.; Wang H.; Yang D.; Zhai Y.; Huang X.; Updated safety and efficacy results of Phase 1 Study of Olverembatinib (HQP1351), a novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in patients with TKI-resistant Chronic Myeloid Leukemia (CML). Blood 2021,138(Suppl. 2),311","journal-title":"Blood"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2020-142142","volume":"136","author":"Jiang Q.","year":"2020","unstructured":"Jiang Q.; Huang X.; Chen Z.; Niu Q.; Shi D.; Li Z.; Hou Y.; Hu Y.; Li W.; Liu X.; Xu N.; Song Y.; Zhang Y.; Meng L.; Hong Z.; Liu B.; Zeng S.; Men L.; Li Y.; Chen S.; Xue M.; Zhu H.; Li H.; Du X.; Lou J.; Zhang X.; Liang Y.; Dai Y.; Lu M.; Wang H.; Jl J.; Yue C.; Yang D.; Zhai Y.; Novel BCR-ABL1 tyrosine kinase inhibitor (TKI) HQP1351 (olverembatinib) is efficacious and well toler-ated in patients with T315I-mutated chronic myeloid leukemia (CML): Results of pivotal (phase II) trials. Blood 2020,136(Suppl. 1),50-51","journal-title":"Blood"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood-2021-153937","volume":"138","author":"Jiang Q.","year":"2021","unstructured":"Jiang Q.; Shi D.; Li Z.; Hou Y.; Hu Y.; Li W.; Liu X.; Song Y.; Zhang G.; Meng L.; Hong Z.; Liu B.; Li Y.; Chen S.; Xue M.; Zhu H.; Li H.; Du X.; Lou J.; Zhang X.; Liang Y.; Dai Y.; Chen Z.; Niu Q.; Men L.; Yang D.; Zhai Y.; Huang X.; Updated results of piv-otal Phase 2 Trials of Olverembatinib (HQP1351) in patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1T315I-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP). Blood 2021,138(Suppl. 2),3598","journal-title":"Blood"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3892\/ijo.2019.4801","volume":"55","author":"Ivanova E.S.","year":"2019","unstructured":"Ivanova E.S.; Tatarskiy V.V.; Yastrebova M.A.; Khamidullina A.I.; Shunaev A.V.; Kalinina A.A.; Zeifman A.A.; Novikov F.N.; Du-tikova Y.V.; Chilov G.G.; Shtil A.A.; PF 114, a novel selective inhibitor of BCR ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells. Int J Oncol 2019,55(1),289-297","journal-title":"Int J Oncol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/leu.2014.326","volume":"29","author":"Mian A.A.","year":"2015","unstructured":"Mian A.A.; Rafiei A.; Haberbosch I.; Zeifman A.; Titov I.; Stroylov V.; Metodieva A.; Stroganov O.; Novikov F.; Brill B.; Chilov G.; Hoelzer D.; Ottmann O.G.; Ruthardt M.; PF-114, a potent and selective inhibitor of native and mutated BCR\/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation. Leukemia 2015,29(5),1104-1114","journal-title":"Leukemia"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1182\/blood-2019-127951","volume":"134","author":"Turkina A.G.","year":"2019","unstructured":"Turkina A.G.; Vinogradova O.; Lomaia E.; Shatokhina E.; Shukhov O.A.; Chelysheva E.Y.; Shikhbabaeba D.; Nemchenko I.; Pe-trova A.; Bykova A.; Zaritskey A.; Siordia N.; Shuvaev V.; Cortes J.E.; Peter Gale R.; Baccarini M.; Ottmann O.; Mikhailov I.; Novikov F.; Shulgina V.; Chilov G.; PF-114: A 4th generation tyrosine kinase-inhibitor for chronic phase chronic myeloid leukaemia in-cluding BCRABL1T315I. Blood 2019,134(Suppl. 1),1638","journal-title":"Blood"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1182\/blood-2021-150120","volume":"138","author":"Turkina A.G.","year":"2021","unstructured":"Turkina A.G.; Vinogradova O.; Lomaia E.; Shatokhina E.; Shukhov O.A.; Zaritskey A.; Chelysheva E.Y.; Shikhbabaeba D.; Nem-chenko I.; Petrova A.; Bykova A.; Shuvaev V.; Siordia N.; Cortes J.E.; Peter Gale R.; Baccarini M.; Ottmann O.; Mikhailov I.; Novikov F.; Shulgina V.; Chilov G.; PF-114 in patients failing prior Tyrosine Kinase-Inhibitor therapy including BCR:ABL1T315I. Blood 2021,138(Suppl. 2),1482","journal-title":"Blood"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrc2723","volume":"9","author":"Levine A.J.","year":"2009","unstructured":"Levine A.J.; Oren M.; The first 30 years of p53: Growing ever more complex. Nat Rev Cancer 2009,9(10),749-758","journal-title":"Nat Rev Cancer"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.18632\/oncotarget.1918","volume":"5","author":"Saiki A.Y.","year":"2014","unstructured":"Saiki A.Y.; Caenepeel S.; Yu D.; Lofgren J.A.; Osgood T.; Robertson R.; Canon J.; Su C.; Jones A.; Zhao X.; Deshpande C.; Payton M.; Ledell J.; Hughes P.E.; Oliner J.D.; MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental onco-genic signaling pathways. Oncotarget 2014,5(8),2030-2043","journal-title":"Oncotarget"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/cpdd.903","volume":"10","author":"Taylor A.","year":"2021","unstructured":"Taylor A.; Lee D.; Allard M.; Poland B.; Greg Slatter J.; Phase 1 Concentration-QTc and cardiac safety analysis of the MDM2 Antago-nist KRT-232 in patients with advanced solid tumors, Multiple Myeloma, or Acute Myeloid Leukemia. Clin Pharmacol Drug Dev 2021,10(8),918-926","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2020-135987","volume":"136","author":"Templeton I.E.","year":"2020","unstructured":"Templeton I.E.; Podoll T.; Krejsa C.M.; Slatter J.G.; A mechanistic physiologically based pharmacokinetic (PBPK) drug interaction mod-el for the mouse double minute 2 (MDM2) inhibitor KRT-232. Blood 2020,136(Suppl. 1),9-10","journal-title":"Blood"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1080\/17474086.2021.1990034","volume":"14","author":"Malik S.","year":"2021","unstructured":"Malik S.; Hassan S.; E\u015fkazan A.E.; Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Expert Rev Hematol 2021,14(11),975-978","journal-title":"Expert Rev Hematol"}],"container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568009622666220613144253","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/205904\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568009622666220613144253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T16:29:43Z","timestamp":1666888183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/205904\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009622666220613144253","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}